Alpha-1 antitrypsin deficiency augmentation therapy market seen reaching $2.68 billion by 2030

The global market for alpha-1 antitrypsin deficiency augmentation therapy is projected to grow from $1.8 billion in 2025 to $2.68 billion by 2030, driven by clinical trials, gene-targeted therapies and new delivery methods. North America held the largest regional share in 2025, while the latest report also highlights rising investment in rare-disease research.

Why it matters: - Alpha-1 antitrypsin deficiency augmentation therapy is used to protect lung tissue in a rare genetic condition linked to low alpha-1 antitrypsin levels. - The market’s projected expansion points to growing demand for treatments that can slow emphysema progression and improve respiratory function. - The forecast also signals more activity in rare-disease research, hospital partnerships and pediatric care.

What happened: - The Business Research Company published its Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Oct. 30, 2026. - The report projects the market will rise from $1.8 billion in 2025 to $1.93 billion in 2026. - The report forecasts the market will reach $2.68 billion by 2030. - The report places the market’s CAGR at 7.3% for the historical period and 8.5% through 2030. - The company also made a free sample report available.

The details: - The therapy involves administering purified alpha-1 antitrypsin protein to patients with insufficient levels. - The treatment aims to protect lung tissue from protease-antiprotease imbalance. - The therapy is designed to slow emphysema progression and improve respiratory function by restoring functional protein levels in the blood and lungs. - Limited treatment options for alpers disease, heightened awareness of rare genetic disorders, hospital-centered care, a growing pediatric patient base and expanded supportive care programs supported historical growth. - Future growth is expected to come from gene-targeted therapies, increased rare-disease research spending, closer hospital-biotech partnerships, innovative drug delivery methods and more specialized pediatric neurology clinics. - Emerging trends include more symptomatic and supportive care, greater focus on rare genetic condition studies, more pediatric neurology treatment options and new drug formulations and delivery technologies. - Rising clinical trials are a major market driver because they test recombinant proteins, gene therapies and long-acting augmentation treatments. - ClinicalTrials.gov data shows U.S. clinical trial registrations increased from 477,203 at the start of 2024 to 558,474 by late 2025. - The report also points to the full market analysis. - North America held the largest regional market share in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast suggests the market is moving from a niche treatment category into a faster-growing segment of rare-disease care. - The rising trial count implies more competition around next-generation therapies, especially gene-based and long-acting options. - The report’s emphasis on pediatric neurology clinics and supportive care suggests broader clinical use cases may be emerging beyond traditional hospital settings.

What's next: - More clinical trials are likely to shape the competitive landscape for augmentation therapies. - Watch for continued investment in gene-targeted approaches and drug-delivery technologies. - Regional growth outside North America may become more visible as the report’s covered markets develop at different speeds.

The bottom line: - Alpha-1 antitrypsin deficiency augmentation therapy is forecast to post steady, above-average growth through 2030, with research activity and therapy innovation driving the market forward.